Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia  by Goodfellow, Jonathan et al.
CLINICAL STUDIES Endothelial Function
Dietary Supplementation With
Marine Omega-3 Fatty Acids Improve
Systemic Large Artery Endothelial
Function in Subjects With Hypercholesterolemia
Jonathan Goodfellow, BSc, MB, MRCP, Michael F. Bellamy, BSc, MB, MRCP,
Mark W. Ramsey, BMedSci, DM, MRCP, Christopher J. H. Jones, MB, FRCP,
Malcolm J. Lewis, MB, PhD, DSc
Cardiff, United Kingdom
OBJECTIVE This work was undertaken to determine whether dietary supplementation with marine
omega-3 fatty acids improve systemic large artery endothelial function in subjects with hyper-
cholesterolemia.
BACKGROUND Marine omega-3 fatty acids improve vascular function, but the underlying mechanism(s) are
unclear. We studied the effects of marine omega-3 fatty acids on large artery endothelial
function in subjects with hypercholesterolemia.
METHODS Hypercholesterolemic subjects with no other known cause for endothelial dysfunction were
recruited to a prospective, placebo-controlled, randomized, double-blind, parallel-group
study. Treatment with omega-3 fatty acids at a dose of 4 g/day (n 5 15/group) was compared
with placebo, at the beginning (day 0) and end (day 120) of a four-month treatment period.
Endothelial function was assessed pre- and posttreatment by noninvasive ultrasonic vessel
wall tracking of brachial artery flow-mediated dilation (FMD).
RESULTS Treatment with marine omega-3 fatty acids resulted in a significant improvement in FMD
(0.05 6 0.12 to 0.12 6 0.07 mm, p , 0.05) and a significant reduction in triglycerides
(2.07 6 1.13 to 1.73 6 0.95 mmol/liter, p , 0.05), whereas treatment with placebo resulted
in no change in FMD (0.03 6 0.10 to 0.04 6 0.10 mm) or triglycerides (2.29 6 2.09 to
2.05 6 1.36 mmol/liter) (both p , 0.05 treated compared with control). Responses to
sublingual glyceryl trinitrate were unchanged.
CONCLUSIONS Marine omega-3 fatty acids improve large artery endothelium-dependent dilation in subjects
with hypercholesterolemia without affecting endothelium-independent dilation. (J Am Coll
Cardiol 2000;35:265–70) © 2000 by the American College of Cardiology
Atherosclerotic coronary artery disease is a major cause of
morbidity and mortality in Western civilization. Athero-
sclerosis may be regarded as the long-term consequence of a
chronic inflammatory condition of large arteries (1), in
which endothelial dysfunction (2) plays a key role. Endo-
thelial function has been assessed in the coronary circulation
by measuring vascular reactivity to intracoronary infusion of
endothelium-dependent agonists such as acetylcholine. Pa-
tients with atherosclerotic coronary artery disease exhibit
paradoxical vasoconstriction (3), as do patients with hyper-
cholesterolemia and angiographically normal coronaries (4).
Such tests are invasive, expensive and not without risk. An
alternative approach is to study vascular reactivity noninva-
sively with ultrasonic assessment of brachial artery flow-
mediated dilation (FMD) (5). The brachial artery is of a
similar size to coronary arteries, and although it is unusual
for the brachial artery to have significant atheroma, brachial
responses have been shown to correlate well with responses
in the coronary circulation for a given individual (6).
Endothelial function can be measured noninvasively by
“wall tracking” of brachial artery dilation in response to
increased flow generated by hyperemia of the hand (7,8).
Flow-related endothelial function has been shown to be
mediated by NO (9,10) and impaired with all known risk
factors for atheroma (11–15). Endothelial dysfunction, thus
measured, appears to be representative of generalized endo-
thelial dysfunction and offers a potentially useful measure of
the susceptibility to atheroma.
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Among dietary interventions that might protect against
atheroma and its complications are diets rich in fish. The
protective effects of diets rich in fish oil are quite strongly
supported by experimental (16,17), epidemiological (18–23)
and clinical trial data (24). Beneficial effects of fish oil
supplementation on endothelial function in resistance arter-
ies in vivo (25) and in vitro (26) have been reported.
Accordingly, we carried out a placebo-controlled four-
month trial of marine omega-3 fatty acids (“fish oil”) in fit
subjects with hypercholesterolemia in order to test whether
omega-3 fatty acids also improved large artery endothelial
function as measured by flow-mediated brachial artery
dilation.
METHODS
Subjects. Thirty subjects were recruited from the Lipid
Clinic at the University Hospital of Wales, Cardiff. All had
confirmed hypercholesterolemia (serum total cholesterol
.6.5 mmol/liter) after a low-fat diet for three months.
Those already on lipid-lowering agents had stable choles-
terol levels, and the dose of lipid-lowering agent remained
unaltered for the duration of the trial. Exclusion criteria
were active smokers, recent ex-smokers (two years), diabe-
tes, hypertension (including treated hypertension) and a
clinical history of coronary, cerebral or peripheral vascular
disease. Subjects taking hormone supplements, vasoactive
medications or proprietary medications such as vitamins,
antioxidants or fish oils were also excluded.
Study design. This was a prospective, placebo-controlled,
randomized, double-blind, parallel-group trial. Effects of
treatment were compared at the beginning (day 0) and end
(day 120) of a four-month treatment period in parallel
groups of subjects with hypercholesterolemia. All subjects
underwent a full clinical examination. Venous blood sam-
ples were obtained, and flow-mediated brachial artery dila-
tion was measured on days 0 and 120.
Marine omega-3 fatty acids. Thirty subjects were re-
cruited and randomly assigned to two groups of 15 subjects
to receive: a) marine omega-3 fatty acids (K85; Pronova a.s,
Oslo, Norway), or b) placebo (corn oil), each as two 1-g
capsules twice daily for 120 days. Baseline characteristics
were similar in both groups (Table 1). The K85 capsules
used in the study were omega-3 concentrate enriched in
eicosapentanoic acid (EPA) and docosahexanoic acid
(DHA) and produced from high-quality whole-body fish
oil. The concentration of these two fatty acids as esters is
about 85%, which is approximately threefold higher than in
Maxepa capsules. K85 also contains 4 IU of vitamin E per
capsule. The corn oil placebo capsules contained no vitamin
E.
Measurement of endothelial function. Flow-mediated
dilation was measured by ultrasonic wall tracking as re-
ported previously (7). The system used comprises a specially
adapted duplex color flow echo machine (Diasonics Spectra)
with a 7.5-MHz linear phased-array transducer (giving high
axial resolution), a personal computer and a 4-Mb high-
speed memory. The brachial artery is identified using the
ultrasound transducer, and anatomical landmarks are iden-
tified to allow repeat studies. A standoff device containing
ultrasound-coupling gel prevents compression of the ante-
rior wall of the artery. The transducer is held in a stereo-
tactic clamp, and a two-dimensional longitudinal B-mode
image of the brachial artery is obtained. The radio frequency
(RF) signals (sampling frequency 1 kHz) from the M-mode
output are digitized and relayed to the wall tracking system
(Vadirec, Medical Systems Arnhem, Oosterbeek, The
Netherlands). On completion of 10-s data acquisition, the
RF signal is displayed so that the position of the anterior
and posterior vessel walls on the RF signal can be identified
and marked. Vessel wall movements are tracked using the
stored RF signals to produce displacement waveforms of the
anterior and posterior vessel walls together with the disten-
sion waveform (diameter change as a function of time). The
distension waveform enables measurement of “end-
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DHA 5 docosahexanoic acid
EPA 5 eicosapentanoic acid
FMD 5 flow-mediated dilation
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VLDL 5 very low density lipoprotein
Table 1. Baseline Characteristics of Subjects in Omega-3 Fatty
Acids Study
Placebo
(n 5 15)
Marine Omega-3
Fatty Acid
(n 5 13)
Age (years) 50 6 12 56 6 13
Male/Female (n) 11/4 8/6
Total cholesterol
(mmol/liter)
7.45 6 0.64 7.85 6 1.64
HDL cholesterol
(mmol/liter)
1.34 6 0.39 1.41 6 0.38
LDL cholesterol
(mmol/liter)
5.31 6 0.73 5.00 6 0.73
Triglyceride (mmol/liter) 2.29 6 2.09 2.07 6 1.13
Glucose (mmol/liter) 4.95 6 0.66 4.95 6 0.59
Body mass index (kg/m2) 25.18 6 2.70 26.90 6 3.04
Smoking status 0 0
Blood pressure 137 6 10 138 6 13
mm Hg 86 6 9 87 6 9
Statin (n) 3 1
Fibrate (n) 1 2
Nil (n) 12 10
No significant differences between the two groups. Data are given as mean 6 SD.
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diastolic” diameter for each beat (theoretical resolution 6
3 mm) (27).
Blood pressure was recorded throughout the study by
photo-plethysmography (Finapres) from a finger cuff on the
middle finger of the ipsilateral arm. Blood flow was mea-
sured throughout the study using an 8-MHz continuous
wave Doppler probe mounted at an angle of 60° in a perspex
block and positioned over the brachial artery distal to the
7.5-MHz probe. The Doppler signals were analyzed by a
spectrum analyser (SciMed Dopstation, Bristol, UK) and
stored on metal audiotape using a high-performance re-
corder (Nakamichi B-100E, Nakamichi Corporation, Ja-
pan). Brachial artery blood flow was calculated by multiply-
ing the mean blood velocity (corrected for Doppler angle) by
the internal brachial artery diameter measured by wall
tracking.
Study protocol. All studies were performed in the morning
in a temperature-controlled room (21°C to 23°C) on fasting
subjects after a 15-min supine rest, with the arm held
outstretched on a pneumatic cushion. Patients were asked to
avoid caffeine-containing beverages for 12 h before the
study. Measurements were made at baseline, during hand
hyperemia and after sublingual glyceryl trinitrate (GTN), an
endothelium-independent vasodilator.
Hand hyperemia. A pediatric sphygmomanometer cuff
was inflated at the wrist to suprasystolic pressure (systolic
pressure 6 50 mm Hg) for 5 min. Blood flow was recorded
from 15 s before until 90 s after cuff release, and internal
brachial artery diameter was measured for 10 s at 60 to 70 s
after cuff release. All measurements were repeated $ 15 min
later until values reached original baseline levels. Flow-
mediated dilation was defined as brachial artery diameter at
60 to 70 s after cuff release minus baseline diameter
(expressed in mm).
GTN. Measurements were repeated 3 min after sublingual
GTN spray (400 mg).
Serum concentrations. Fasting venous blood samples were
obtained at each study for measurement of total serum
cholesterol, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, very low density
lipoprotein (VLDL) cholesterol (calculated), triglyceride
and glucose. Urea and electrolytes and liver function were
also measured.
Statistics. Data are presented as mean 6 SD. Data were
tested for normality using the Shapiro-Wilks test. Where
normality was established unpaired Student’s t tests were
used to make comparisons between groups and Student’s
paired t test to make comparisons within groups. p , 0.05
was regarded as significant.
Ethical approval. Ethical approval for this study was
granted by the local research and ethics committee of South
Glamorgan Health Authority. All subjects gave written
informed consent. The investigation conformed to the
principles outlined in the Declaration of Helsinki.
RESULTS
There were no significant differences between the treatment
groups at baseline (Table 1). Of the 15 subjects allocated to
each group, 28 completed the study. The two subjects who
did not return for the second scan were in the fish oil group;
no reasons for leaving the study were reported. No adverse
side effects were reported. Compliance with treatment was
assessed by a count of capsules returned at study end and
was considered satisfactory (.95% for placebo and marine
omega-3 fatty acids).
Changes in brachial artery blood flow immediately after
wrist cuff release (peak flow, 1 min after cuff release and
3 min after sublingual GTN) were similar in all groups
before and after treatment (Fig. 1A). Flow-mediated dila-
tion increased significantly after omega-3 fatty acids treat-
ment compared with placebo (Table 2, Fig. 1B). Treatment
with omega-3 fatty acids significantly reduced triglyceride
levels (Table 2) but had no effect on serum concentration
of total cholesterol, VLDL, LDL or HDL cholesterol,
whereas treatment with placebo had no significant effect on
the lipid profiles (Table 2).
There was no correlation between the improvement in
endothelium-dependent FMD and the reduction in triglyc-
erides in the marine omega-3 fatty acids group.
Glyceryl trinitrate-induced dilation was similar pre- and
posttreatment in both groups (Table 2, Fig. 1C).
DISCUSSION
The major findings of this double-blind placebo-controlled
study are that marine omega-3 fatty acids (fish oils) improve
endothelial function in systemic large arteries in patients
with hypercholesterolemia. This study also confirms the loss
of FMD in the brachial artery, reflecting impaired
endothelium-derived nitric oxide (NO) activity in hyper-
cholesterolemic patients as previously reported (28,29). It
confirms also that vascular smooth muscle dilator respon-
siveness to NO is preserved, as evidenced by the normal
dilator response to GTN.
Dietary supplementation with marine omega-3 fatty acids
for four months resulted in a significant improvement in
endothelium-dependent FMD of the brachial artery. This
artery is of a similar size to the coronary arteries, and
brachial responses have been shown to correlate well with
responses in the coronary circulation for a given individual
(6). There was a significant decrease in serum triglycerides
with omega-3 fatty acids supplementation, which has pre-
viously been reported (30). In this study, the improvement
in endothelial function did not correlate with the reduction
in triglycerides, which is not unexpected, as our subjects had
hypercholesterolemia with significantly elevated total and
LDL cholesterol levels, with only modestly elevated triglyc-
eride levels. Hypertriglyceridemia is not as strongly associ-
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ated with coronary atherosclerosis (31) as elevated LDL
cholesterol (32), and when multivariate analysis is used to
correct for LDL and HDL cholesterol, much of the
association with hypertriglyceridemia disappears (33). Fur-
ther support for a lack of association between hypertriglyc-
eridemia and endothelial function comes from a recent
study that demonstrated that severe hypertriglyceridemia
was not associated with significant dysfunction of the
L-arginine/NO pathway in forearm resistance vessels (34).
Possible mechanism(s) for improvement in endothelial
function. The mechanism underlying the improvement in
endothelial function in patients treated with marine
omega-3 fatty acids in this study is unclear. We did not give
indomethacin, therefore, we cannot exclude the possibility
that vasodilator prostaglandins played a role. However,
based on animal studies (16) and a recent clinical study (26),
this would appear to be unlikely. Recent evidence suggests
that the mechanism(s) responsible for the benefit seen with
a fish oil-rich diet is likely to relate to changes in membrane
bilipid layer composition with multiple potential effects on
endothelial function. The recent in vitro small artery study
by Goode et al. (26) demonstrated that the greatest im-
provement in endothelial function occurred in those pa-
tients who had the greatest increase in membrane EPA and
DHA, as reflected by increases in these fatty acids in the red
cell membrane. Hence, it is possible that dietary supple-
mentation with marine omega-3 fatty acids may change the
membrane fluidity of endothelial cells, promoting increased
synthesis and/or release of NO. The marine omega-3 fatty
acids preparation we used contains a small amount of
antioxidant vitamin E (equal to approximately 16 IU vita-
min E/day), which theoretically may be expected to have an
effect. In a study of similar design, we have shown dietary
supplementation with 20 IU vitamin E/day for four months
had no benefit in hypercholesterolemic subjects (unpub-
lished data, J.G.), as have others (35). Feeding humans fish
oils has been shown to reduce oxygen-derived free radical
formation in neutrophils and monocytes, and to enhance
NO production by cultured human endothelial cells (36).
Speculatively, it is also possible that a reduction in the
formation of oxygen derived free radicals by endothelial cells
and thus increased bioavailability of NO contributed to the
effects observed in this study.
Clinical implications. This study adds evidence relevant to
the complex but important issue of dietary reduction of
atherogenesis, given the key-initiating role of endothelial
dysfunction. Marine omega-3 fatty acids offer attractive
potential, which has recently been supported by evidence of
clinical benefit (37). Clinical evidence is necessarily
weighted towards changes in the end-stage complications of
coronary artery disease, and this may be susceptible to
measures that alter plaque cap inflammation and vulnera-
bility to fissuring and thrombosis as well as the intrinsic
process of atherogenesis. The latter changes may be longer
term and less readily detectable. This study, through the
measurement of endothelial function indices, supports a
possible future role for omega-3 fatty acids and may help to
Figure 1. The effect of four months of treatment with placebo and
omega-3 fatty acids on the following. A, Brachial artery blood flow
(expressed as percent change from baseline) at: peak flow imme-
diately after wrist cuff deflated, 1 min after cuff deflated and 3 min
after 400 mg sublingual GTN. There were no significant differ-
ences between groups. B, Flow-mediated dilation expressed as
absolute change (mm) from baseline diameter. There is a significant
improvement within the omega-3 fatty acids group posttreatment
(*p , 0.05) and when compared with placebo posttreatment (**p ,
0.05). C, Glyceryl trinitrate-mediated dilation expressed as absolute
change (mm) from baseline diameter. There were no significant
differences between groups. Data are presented as mean 6 SEM.
Solid bars 5 posttreatment; Open bars 5 pretreatment.
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explain the benefits shown in epidemiological studies of
populations consuming a fish-rich diet.
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